CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
淋巴瘤 CD19 靶向 CAR-T 细胞治疗后的第二原发恶性肿瘤：意大利 CART-SIE 研究报告
英文原题：Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
查看英文原题
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
抗 BCMA 或抗 CD19 嵌合抗原受体（CAR）T 细胞疗法后已有继发原发恶性肿瘤（SPM）报告。尽管化疗、放疗等既往治疗的细胞毒作用已得到充分证实，但有关 CAR-T 免疫疗法相关风险的数据有限。本研究旨在分析意大利前瞻性观察性 CART-SIE 研究中 651 例患者的 SPM 发生率。SPM 记录于 4.3%（28/651）患者中，其中最常见的是血液系统恶性肿瘤。总之，本重度经治患者队列中接受 CAR-T 后 SPM 发生率相对较低，与既往研究结果一致。
展开英文摘要原文
Secondary primary malignancies (SPM) have been reported after anti-BCMA or anti-CD19 chimeric antigen receptor (CAR)-T-cell therapies. While the cytotoxic effect of antecedent therapies, including chemotherapy and radiotherapy, has been well established, few data are available on risk related to CAR-T immunotherapies. The study aimed to analyse the incidence of SPM in 651 patients enrolled in the Italian prospective observational CART-SIE study. SPMs were documented in 4. 3% (28/651), and the most frequent SPMs were haematological malignancies.
In conclusion, the frequency of SPMs in our cohort of heavily pretreated patients receiving CAR-T was relatively low and consistent with previous studies.
论文信息
- 作者
- Barone A、Chiappella A、Casadei B、Bramanti S、Ljevar S、Chiusolo P、Di Rocco A、Tisi MC
- 单位
- Chair of Hematology, University of Milan, Milan, Italy.Italy
- 文献类型
- 多中心研究 · 观察性研究
- 期刊
- British journal of haematology2024 Oct
- 原文标识
- PubMed 38877876 · DOI 10.1111/bjh.19590